Tesamorelin

Step	Weeks	Dose	Purpose
Weeks 1–26	—	2 mg	Visceral fat reduction protocol per FDA-approved indication

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Reconstitution and handling notes

Stacking Notes

Additional Dosage Notes

Tesamorelin has the strongest clinical evidence base of any GHRH secretagogue due to its FDA development program. The key trials:

Phase 3 pivotal trial - Falutz et al., 2007 (NEJM)

A 26-week double-blind placebo-controlled trial in 412 HIV-infected patients with excess abdominal fat. Tesamorelin 2 mg/day SC reduced visceral adipose tissue (VAT) by 15.2% versus a 5.0% increase on placebo (p<0.001), and improved triglycerides and the total-to-HDL cholesterol ratio. Mean IGF-1 rose 81% with tesamorelin versus a 5% decline on placebo (p<0.001). The trial established the FDA-approval pathway and is the foundational visceral-fat efficacy citation (Falutz et al., 2007).

52-week extension - Falutz et al., 2010

Open-label extension of the pivotal trial. Patients who continued tesamorelin maintained VAT reduction; patients who switched from placebo to tesamorelin achieved similar VAT reduction. Importantly, patients who discontinued tesamorelin regained VAT within 26 weeks - demonstrating the therapy is suppressive, not curative. No new safety signals over 52 weeks ([Falutz et al., 2010]).

NAFLD - Stanley et al., 2014 (JAMA)

A 6-month double-blind randomized trial in 50 antiretroviral-treated HIV patients with abdominal fat accumulation. Tesamorelin 2 mg/day reduced liver fat with a net treatment effect of -2.9% (lipid-to-water percentage) and significantly reduced visceral adipose tissue, with no significant change in fasting glucose at 6 months. This was the first randomized demonstration of a tesamorelin effect on liver fat (Stanley et al., 2014).

NAFLD Phase 2b - Stanley et al., 2019 (Lancet HIV)

A 12-month double-blind randomized trial in 61 HIV patients with confirmed NAFLD (hepatic fat fraction >=5%). Tesamorelin 2 mg/day reduced hepatic fat fraction by an absolute -4.1%, a 37% relative reduction from baseline (p=0.016), and 35% of treated patients reached a hepatic fat fraction below 5% versus 4% on placebo. Fasting glucose and HbA1c did not differ between groups. This is the strongest NAFLD-specific evidence and underpins the off-label fatty-liver use case (Stanley et al., 2019).

Non-HIV obese adults - Makimura et al., 2012 (JCEM)

A 12-month double-blind randomized trial in 60 abdominally obese adults with reduced GH secretion (a non-HIV population). Tesamorelin 2 mg/day selectively reduced visceral adipose tissue (treatment effect 35 cm; p=0.003) without reducing subcutaneous fat, and improved triglycerides, C-reactive protein, and carotid intima-media thickness, without worsening glucose or HbA1c. This is the key evidence that the visceral-fat effect extends beyond the HIV population and supports off-label metabolic use (Makimura et al., 2012).

Pharmacokinetics / nonclinical pharmacology - Ferdinandi et al., 2007

Characterization of tesamorelin (TH9507) consistent with a short plasma half-life (~30-50 minutes) and no accumulation on daily dosing, supporting the once-daily 2 mg regimen ([Ferdinandi et al., 2007]).

Cognition - Ellis et al., 2025 (J Infect Dis)

A 6-month phase 2 open-label randomized trial in 73 people with HIV and abdominal obesity (tesamorelin vs standard of care). Tesamorelin raised IGF-1 and reduced waist circumference, but the between-group difference in neurocognitive performance was not significant (p=0.67). The authors concluded there was no clear cognitive benefit from short-term abdominal-fat reduction, noting the study was underpowered and had no placebo arm. Any earlier claim of a tesamorelin cognitive benefit is not supported by this trial (Ellis et al., 2025).

Long-term safety - extension data

Across the phase 3 program and its extensions (roughly one year of controlled exposure plus open-label follow-up), tesamorelin showed no acromegalic complications and no clinically significant glucose intolerance beyond transient early elevations; longer-term safety beyond the trial window is extrapolated from the broader GH/IGF-1 literature.

What's missing from the evidence base

• No direct head-to-head vs CJC-1295 with DAC or Sermorelin
• Limited long-term (>2 year) safety data outside the HIV population
• No pediatric or elderly-specific efficacy trials
• Cardiovascular outcomes (MACE) data remains limited
• Oncologic safety in cancer-survivor populations is inferred from the general GH/IGF-1 literature, not tesamorelin-specific

The off-label biohacker use at 2 mg/day for non-HIV metabolically-unhealthy adults is extrapolated from the HIV lipodystrophy and NAFLD trials plus the non-HIV obese-adult trial (Makimura 2012) - not from dedicated trials in otherwise-healthy biohackers.

Tesamorelin has a well-characterized side-effect profile from the FDA approval program, which is a significant advantage over non-approved GHRH analogs.

Common (>10% in Phase 3 trials)

• Injection site reactions — erythema, pruritus, pain at site; most frequent adverse event (~22% of patients); usually mild and resolves with site rotation
• Arthralgia (joint aches) — IGF-1-mediated connective tissue effect; typically appears 4-8 weeks into dosing and stabilizes
• Pain in extremities — related to fluid shifts and peripheral tissue expansion
• Myalgia — mild muscle aches, also from IGF-1-mediated connective tissue changes
• Peripheral edema — dose-dependent GH-mediated fluid retention; mild and usually resolves within weeks

Uncommon (1-10%)

• Carpal tunnel symptoms — fluid-shift-mediated peripheral compression; should prompt dose reduction or discontinuation
• Paresthesias (hand tingling) — early sign of fluid retention
• Insulin resistance / elevated fasting glucose — all GH-elevating therapies impair glucose tolerance; in Phase 3 trials, HbA1c rose by ~0.1% absolute on tesamorelin vs placebo — clinically small but monitor
• Rash / urticaria — hypersensitivity-spectrum reactions

Rare but important

• Hyperglycemia / new-onset diabetes — rare in the Phase 3 trials; however, patients with pre-existing diabetes or pre-diabetes require close monitoring
• Fluid retention with CHF — contraindicated in patients with acute critical illness, heart failure, or severe edema
• IGF-1 elevation above age-adjusted upper limit — ~5% of patients in Phase 3 had IGF-1 > ULN; requires dose reduction

Black box / boxed warnings — Tesamorelin has NO FDA black box warning. This is notable: recombinant GH (Somatropin) carries boxed warnings for critical-illness mortality; tesamorelin does not.

Contraindications per FDA label

• Disruption of the hypothalamic-pituitary axis (pituitary tumor removal, hypopituitarism, hypothalamic injury)
• Active malignancy — absolute; GH/IGF-1 axis may accelerate tumor growth
• Pregnancy — contraindicated
• Pediatrics — not studied

What tesamorelin DOES NOT do

• Does NOT elevate prolactin or cortisol (unlike GHRP-2/6 / hexarelin)
• Does NOT cause the continuous GH elevation of CJC-1295-DAC
• Does NOT cause the acromegalic-body-composition changes of chronic recombinant GH (because the pulse pattern preserves physiologic regulation)
• Does NOT cause injection-site lipodystrophy seen with some older peptide injections

Monitoring requirements

Per FDA label and standard clinical practice:

• Baseline: IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, thyroid (TSH, free T4)
• Weeks 4-8: IGF-1 — target within age-adjusted reference range; dose-reduce or discontinue if ULN exceeded
• Quarterly (on long-term therapy): HbA1c, fasting glucose, liver function, IGF-1
• Annually: Reassess need for continued therapy (it is suppressive, not curative)

Long-term safety framing

The Phase 3 + extension data covers ~2 years; beyond that, safety is extrapolated from the broader GH/IGF-1 literature. Active surveillance for malignancy (general cancer screening appropriate for age and sex), periodic IGF-1 monitoring, and glucose/HbA1c surveillance are the standard clinical practices for adults on tesamorelin beyond 2 years.